Dr. Amy Wei Wei Zhou, MD

Dr. Zhou practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Zhou's NPI, 1831331990, was assigned on April 3, 2009. Dr. Zhou graduated from Wayne State University School of Medicine in 2009. Dr. Zhou holds Missouri license 2016007986.

Dr. Zhou's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Zhou also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Zhou's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Zhou is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Zhou to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhou practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Zhou's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Zhou is licensed in Missouri.

CMS data shows 14,054 Medicare services from Dr. Zhou across 13 procedure codes in 2024, for 304 Medicare patients. Medicare paid $353,181 for them.

CMS counts 304 Medicare patients who saw Dr. Zhou in 2024. The largest group is 65 to 74, with 134 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhou's median patient age at 70, with 59% women.

In 2024, Dr. Zhou wrote 648 Medicare Part D claims for 106 patients. 54% of them were for generic drugs. CMS names the drug for 522 of them, across 15 drugs with 11 or more claims each, at $2,766,813 in total drug cost. In 2023, CMS named 451 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Zhou for performance year 2024, reported as part of a group. Dr. Zhou accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Zhou, published from 2014 to 2025. 2014 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular and Cholangiocarcinoma. Dr. Zhou has published most often in J Natl Compr Canc Netw. Dr. Zhou's most frequent co-authors are Manik A. Amin, MD, Amber Afzal, MD and Makiko Ban-Hoefen, MD.

Dmand AI links Dr. Zhou to 4 clinical trials, 2 of them phase 1 studies. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Juvenile and Primary Myelofibrosis. Washington University School of Medicine sponsors the most, 4.

CMS Open Payments shows 89 general payments to Dr. Zhou from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. Incyte Corporation paid the most, $56,918.

Dr. Zhou graduated from Wayne State University School of Medicine in 2009.